{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T08:46:37Z","timestamp":1781945197506,"version":"3.54.5"},"reference-count":23,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T00:00:00Z","timestamp":1681344000000},"content-version":"unspecified","delay-in-days":12,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Open Heart"],"accepted":{"date-parts":[[2023,3,27]]},"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Patients with cancer are at increased bleeding risk, and anticoagulants increase this risk even more. Yet, validated bleeding risk models for prediction of bleeding risk in patients with cancer are lacking. The aim of this study is to predict bleeding risk in anticoagulated patients with cancer.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We performed a study using the routine healthcare database of the Julius General Practitioners\u2019 Network. Five bleeding risk models were selected for external validation. Patients with a new cancer episode during anticoagulant treatment or those initiating anticoagulation during active cancer were included. The outcome was the composite of major bleeding and clinically relevant non-major (CRNM) bleeding. Next, we internally validated an updated bleeding risk model accounting for the competing risk of death.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The validation cohort consisted of 1304 patients with cancer, mean age 74.0\u00b110.9 years, 52.2% males. In total 215 (16.5%) patients developed a first major or CRNM bleeding during a mean follow-up of 1.5 years (incidence rate; 11.0 per 100 person-years (95% CI 9.6 to 12.5)). The c-statistics of all selected bleeding risk models were low, around 0.56. Internal validation of an updated model accounting for death as competing risk showed a slightly improved c-statistic of 0.61 (95% CI 0.54 to 0.70). On updating, only age and a history of bleeding appeared to contribute to the prediction of bleeding risk.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Existing bleeding risk models cannot accurately differentiate bleeding risk between patients. Future studies may use our updated model as a starting point for further development of bleeding risk models in patients with cancer.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/openhrt-2023-002273","type":"journal-article","created":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T13:54:20Z","timestamp":1681394060000},"page":"e002273","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["External validation and updating of prediction models of bleeding risk in patients with cancer receiving anticoagulants"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0535-9253","authenticated-orcid":false,"given":"EM","family":"Trinks-Roerdink","sequence":"first","affiliation":[{"name":"Department of General Practice & Nursing Science, Julius Centre for Health Sciences and Primary Care, UMCU, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"GJ","family":"Geersing","sequence":"additional","affiliation":[{"name":"Department of General Practice & Nursing Science, Julius Centre for Health Sciences and Primary Care, UMCU, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MEW","family":"Hemels","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Rijnstate Hospital, Arnhem, The Netherlands"},{"name":"Department of Cardiology, Radboudumc, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"IC","family":"van Gelder","sequence":"additional","affiliation":[{"name":"Department of Cardiology, UMCG, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"FA","family":"Klok","sequence":"additional","affiliation":[{"name":"Department of Medicine - Thrombosis and Haemostasis, LUMC, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"van Smeden","sequence":"additional","affiliation":[{"name":"Department of Epidemiology & Health Economics, Julius Centre for Health Sciences and Primary Care, UMCU, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"FH","family":"Rutten","sequence":"additional","affiliation":[{"name":"Department of General Practice & Nursing Science, Julius Centre for Health Sciences and Primary Care, UMCU, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"van Doorn","sequence":"additional","affiliation":[{"name":"Department of General Practice & Nursing Science, Julius Centre for Health Sciences and Primary Care, UMCU, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,4,13]]},"reference":[{"key":"2025081612184566000_10.1.e002273.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2009.12.023"},{"key":"2025081612184566000_10.1.e002273.2","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/S0049-3848(14)50009-6","article-title":"Bleeding complications during anticoagulant treatment in patients with cancer","volume":"133 Suppl 2","author":"Kamphuisen","year":"2014","journal-title":"Thromb Res"},{"key":"2025081612184566000_10.1.e002273.3","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1111\/jth.15739","article-title":"Incidence and determinants of thrombotic and bleeding complications in patients with glioblastoma","volume":"20","author":"Kaptein","year":"2022","journal-title":"J Thromb Haemost"},{"key":"2025081612184566000_10.1.e002273.4","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/ajh.25494","article-title":"Bleeding incidence and risk factors among cancer patients treated with anticoagulation","volume":"94","author":"Angelini","year":"2019","journal-title":"Am J Hematol"},{"key":"2025081612184566000_10.1.e002273.5","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1080\/10245330500093237","article-title":"Management of bleeding in the terminally ill patient","volume":"10","author":"Prommer","year":"2005","journal-title":"Hematology"},{"key":"2025081612184566000_10.1.e002273.6","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1111\/jth.15776","article-title":"Management of bleeding risk in patients who receive anticoagulant therapy for venous thromboembolism: communication from the ISTH SSC Subcommittee on predictive and diagnostic variables in thrombotic disease","volume":"20","author":"den Exter","year":"2022","journal-title":"J Thromb Haemost"},{"key":"2025081612184566000_10.1.e002273.7","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00280-2016"},{"key":"2025081612184566000_10.1.e002273.8","doi-asserted-by":"publisher","DOI":"10.1378\/chest.10-0134"},{"key":"2025081612184566000_10.1.e002273.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2011.03.031"},{"key":"2025081612184566000_10.1.e002273.10","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1136\/heartjnl-2019-316305","article-title":"Tailoring anticoagulant treatment of patients with atrial fibrillation using a novel bleeding risk score","volume":"107","author":"Chu","year":"2020","journal-title":"Heart"},{"key":"2025081612184566000_10.1.e002273.11","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehv476","article-title":"The orbit bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation","volume":"36","author":"O\u2019Brien","year":"2015","journal-title":"Eur Heart J"},{"key":"2025081612184566000_10.1.e002273.12","doi-asserted-by":"publisher","DOI":"10.7326\/M18-1376"},{"key":"2025081612184566000_10.1.e002273.13","doi-asserted-by":"crossref","DOI":"10.1186\/s12913-018-3528-5","article-title":"Routine primary care data for scientific research, quality of care programs and educational purposes: the Julius General Practitioners\u2019 Network (JGPN)","volume":"18","author":"Smeets","year":"2018","journal-title":"BMC Health Serv Res"},{"key":"2025081612184566000_10.1.e002273.14","unstructured":"Website Julius General Practitioners Network. 2022. Available: https:\/\/juliuscentrum.umcutrecht.nl\/en\/studies-and-cohorts\/julius-general-practitioners-network"},{"key":"2025081612184566000_10.1.e002273.15","doi-asserted-by":"publisher","DOI":"10.1093\/fampra\/13.3.294"},{"key":"2025081612184566000_10.1.e002273.16","doi-asserted-by":"crossref","first-page":"e417","DOI":"10.1055\/s-0040-1721499","article-title":"The number of concomitant drugs and the safety of direct oral anticoagulants in routine care patients with atrial fibrillation","volume":"4","author":"van den Dries","year":"2020","journal-title":"TH Open"},{"key":"2025081612184566000_10.1.e002273.17","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13140"},{"key":"2025081612184566000_10.1.e002273.18","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2021-069249","article-title":"Validation of prediction models in the presence of competing risks: a guide through modern methods","volume":"377","author":"van Geloven","year":"2022","journal-title":"BMJ"},{"key":"2025081612184566000_10.1.e002273.19","doi-asserted-by":"publisher","DOI":"10.1177\/962280218784726"},{"key":"2025081612184566000_10.1.e002273.20","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1055\/s-0041-1735251","article-title":"Estimating bleeding risk in patients with cancer-associated thrombosis: evaluation of existing risk scores and development of a new risk score","volume":"122","author":"de Winter","year":"2022","journal-title":"Thromb Haemost"},{"key":"2025081612184566000_10.1.e002273.21","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1056\/NEJMoa2113194","article-title":"Milvexian for the prevention of venous thromboembolism","volume":"385","author":"Weitz","year":"2021","journal-title":"N Engl J Med"},{"key":"2025081612184566000_10.1.e002273.22","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S0140-6736(22)00456-1","article-title":"Safety of the oral factor xia inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study","volume":"399","author":"Piccini","year":"2022","journal-title":"Lancet"},{"key":"2025081612184566000_10.1.e002273.23","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1093\/ije\/dyab256","article-title":"Lessons learnt when accounting for competing events in the external validation of time-to-event prognostic models","volume":"51","author":"Ramspek","year":"2022","journal-title":"Int J Epidemiol"}],"container-title":["Open Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/openhrt-2023-002273","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T19:18:55Z","timestamp":1755371935000},"score":1,"resource":{"primary":{"URL":"https:\/\/openheart.bmj.com\/lookup\/doi\/10.1136\/openhrt-2023-002273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,4,13]]},"published-print":{"date-parts":[[2023,4]]}},"alternative-id":["10.1136\/openhrt-2023-002273"],"URL":"https:\/\/doi.org\/10.1136\/openhrt-2023-002273","relation":{},"ISSN":["2053-3624"],"issn-type":[{"value":"2053-3624","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4]]}}}